<DOC>
	<DOCNO>NCT01254331</DOCNO>
	<brief_summary>This open-label , multi-center study local environment evaluate safety effect disease activity regard reduction sign symptoms 6 month treatment patient moderate severe active rheumatoid arthritis experience inadequate response non-biologic DMARD . Tocilizumab 8 mg/kg administer intravenous infusion every 4 week total 6 infusion monotherapy combination methotrexate ( MTX ) . The anticipated time study treatment 24 week .</brief_summary>
	<brief_title>An Open-label Study With Tocilizumab Patients With Rheumatoid Arthritis Local Environment</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient &gt; /=18 year age Moderate severe rheumatoid arthritis define DAS 28 &gt; 3.2 Body weight &lt; /=150 kg Patient least 1 nonbiologic DMARD stable dose least 8 week time prior study start Inadequate clinical response stable dose nonbiologic DMARD Major surgery within 8 week prior screen plan major surgery within 6 month follow enrollment Rheumatic autoimmune disease rheumatoid arthritis ( RA ) Functional class IV define ACR classification History current inflammatory joint disease RA Previous treatment cell deplete therapy Previous treatment methotrexate Previous treatment tocilizumab Previous treatment biologic drug use treatment RA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>